We chose three potential target proteins such as TFGF-Beta, BMP2, and FGFR to validate their differential expressions using selection reaction monitoring (SRM) mass spectrometry methodology using a newly recruited sample set of high-grade sarcoma patients. The gene discussed is BMP2; the disease is sarcoma.